-Astellas throws in the towel! Gives up bid for CV Therapeutics. [Bloomberg]

-Orexo’s novel sublingual formulation of Ambien, aka Sublinox, receives FDA approval. [TMCNet]

-Sanofi’s Multaq (dronedarone) got a nod from the FDA for delaying symptoms of atrial fibrillation and reducing hospitalization. [Reuters]

-United Therapeutics took a hit today when they announced the FDA had concerns with their inhaled version of treprostinil. [BioSpace]

-Check out Xconomy’s take on how healthcare bankers can adapt to the recession. [Xconomy]

-Everyone is talking about the new peanut allergy results, but is it a drug? Where’s the IP? [WebMD]

-DaVinci Biosciences reported encouraging clinical results using stem cells to treat spinal cord injuries. [FierceBioResearcher]

Image from Bloomberg

Related Posts